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Polygenic determinants of white matter volume derived from
GWAS lack reproducibility in a replicate sample
S Papiol1,2,3,7, M Mitjans1,3,4,7, F Assogna5, F Piras5, C Hammer1, C Caltagirone6, B Arias3,4, H Ehrenreich1,2 and G Spalletta5
A recent publication reported an exciting polygenic effect of schizophrenia (SCZ) risk variants, identiﬁed by a large genome-wide
association study (GWAS), on total brain and white matter volumes in schizophrenic patients and, even more prominently, in
healthy subjects. The aim of the present work was to replicate and then potentially extend these ﬁndings. According to the original
publication, polygenic risk scores—using single nucleotide polymorphism (SNP) information of SCZ GWAS—(polygenic SCZ risk
scores; PSS) were calculated in 122 healthy subjects, enrolled in a structural magnetic resonance imaging (MRI) study. These scores
were computed based on P-values and odds ratios available through the Psychiatric GWAS Consortium. In addition, polygenic white
matter scores (PWM) were calculated, using the respective SNP subset in the original publication. None of the polygenic scores,
either PSS or PWM, were found to be associated with total brain, white matter or gray matter volume in our replicate sample. Minor
differences between the original and the present study that might have contributed to lack of reproducibility (but unlikely explain it
fully), are number of subjects, ethnicity, age distribution, array technology, SNP imputation quality and MRI scanner type. In contrast
to the original publication, our results do not reveal the slightest signal of association of the described sets of GWAS-identiﬁed SCZ
risk variants with brain volumes in adults. Caution is indicated in interpreting studies building on polygenic risk scores without
replication sample.
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INTRODUCTION
The Psychiatric Genome-Wide Association Study (GWAS) Consortium
has recently published a large GWAS, including 9394 schizophrenia
(SCZ) cases and 12 462 healthy controls, identifying common
variants that contribute to SCZ susceptibility with relatively small
odds ratios.1 Besides these genome-wide signiﬁcant loci, evidence
has been accruing that a signiﬁcant proportion of the risk for SCZ
may lie in markers not achieving genome-wide signiﬁcance in
GWAS. For instance, a quantitative polygenic SCZ risk score (PSS)
was calculated based on the nominally associated alleles in a
discovery sample. This polygenic score explained up to 3% of
variance in SCZ in a number of independent samples.2 Several
authors have subsequently explored whether such a polygenic
effect might be associated not only with the disease but also with
disease-relevant phenotypes. Although some studies described
associations for example, with cognitive aging3 or with a functional
imaging substrate of working memory processing,4 others reported
a lack of association with psychosis dimensions5 or intelligence.6
Along these lines, a recent study investigated the polygenic
effect of SCZ-associated single nucleotide polymorphisms (SNPs) on
brain volume (total brain, white matter and gray matter).7 The
proportion of variance explained by the PSS was around 5% for
both total brain and white matter volumes. The authors
subsequently generated a polygenic white matter score (PWM)
out of those 2020 SCZ-related SNPs showing the most signiﬁcant
associations with white matter volume in their sample. This PWM,
that is, a ﬁnal subset of 186 SNPs, inﬂuenced white matter volume
most strongly. Importantly, effects were not only detected in
patients but also in healthy control subjects, leading to the author’s
assumption that 'a relatively small subset of SCZ genetic risk
variants is related to the normal development of white matter’.7
Considering the potentially high general importance of these
ﬁndings for the complex genetics and the disease-unrelated
biological grounds of adult brain dimensions, the present study
has been designed to replicate (i) the PSS and (ii) the PWM effects
on total brain and white matter volume in healthy subjects.
MATERIALS AND METHODS
Participants and inclusion criteria
The study was approved by the Santa Lucia Foundation Ethical Committee
and performed in accordance with the Helsinki Declaration. After signing
an informed consent form, 122 healthy subjects of Italian origin were
included. Participants were consecutively recruited by local advertisement
from universities, community recreational centers and hospitals (person-
nel). Inclusion criteria were age 20–80 years and suitability for magnetic
resonance imaging (MRI) scanning. Exclusion criteria included: (i) suspicion
of cognitive impairment (score ⩽26) or dementia based on Mini Mental
State examination,8 the Mental Deterioration Battery9 and the NINCDS-
ADRDA criteria for dementia;10 (ii) subjective complaint of memory
difﬁculties or of any other cognitive deﬁcit, interfering with daily living;
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(iii) presence of major non-stabilized medical illnesses (that is, non-
stabilized diabetes, obstructive pulmonary disease or asthma, hematolo-
gic/oncologic disorders, vitamin B12 or folate deﬁciency, pernicious
anemia, clinically signiﬁcant and unstable active gastrointestinal, renal,
hepatic, endocrine or cardiovascular disorders and recently treated
hypothyroidism); (iv) known or suspected history of alcoholism, drug
dependence and abuse, head trauma and mental disorders according to
the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition–
Text Revision (DSM-IV-TR) criteria (all subjects were interviewed by
Structured Clinical Interview for DSM disorders–NonPatient edition (SCID-
NP), DSM-IV-TR);11 (v) presence of vascular brain lesions, brain tumor and/
or marked cortical and subcortical atrophy on MRI scan. In particular, the
presence, severity and location of vascular lesions were rated according to
a protocol designed for the Rotterdam Scan Study.12 Generally, they were
considered present in cases of hyperintense lesions on both proton-
density and T2-weighted (see image acquisition) and rated semiquantita-
tively as 0 (none), 1 (pencil-thin lining), 2 (smooth halo) or 3 (large
conﬂuent) for three separate regions; adjacent to frontal horns (frontal
caps), adjacent to the wall of the lateral ventricles (bands) and adjacent to
the occipital horns (occipital caps). The total vascular lesion load was
calculated by adding the region-speciﬁc scores (range 0–9). In the present
study, only participants rated 0–1 were included.
Image acquisition and processing
All participants underwent the same imaging protocol, which included
standard clinical sequences (Fluid Attenuated Inversion Recovery (FLAIR),
Proton Density-T2-weighted) and a whole-brain high-resolution T1-
weighted sequence obtained in the sagittal plane using a modiﬁed driven
equilibrium Fourier transform sequence (TE/TR= 2.4/7.92ms, ﬂip angle:
15°, voxel size: 1 mm3) using a 3 T Allegra MR imager (Siemens, Erlangen,
Germany) with a standard quadrature head coil. All planar sequence
acquisitions were obtained in the plane of the anterior commissure–-
posterior commissure line. Particular care was taken to center the subject
in the head coil and to restrain the subject’s movements with cushions and
adhesive medical tape. MRI-based quantiﬁcation of cerebral volumes was
performed using Freesurfer (v.4.05) software package (http://surfer.nmr.
mgh.harvard.edu). Freesurfer includes a sophisticated automated segmen-
tation algorithm, which delineates gross brain anatomy into a series of
cortical and subcortical labels. The stream consists of ﬁve different stages,
fully described elsewhere.13,14 Initially, the MRI volumes were registered to
the Talairach space and the output images were intensity normalized. At
the next stage, the skull was automatically stripped off the three-
dimensional anatomical data set by employing a hybrid method that uses
both watershed algorithms and deformable surface models. At this stage,
manual intervention is needed to visualize and edit areas of skull and the
areas of cortex or cerebellum that should be corrected. After skull
stripping, the output brain mask was labeled using a probabilistic atlas15
and a complex algorithm combining information on image intensity,
probabilistic atlas location and the local spatial relationships between
structures.16–18 For the purpose of this study, calculated volumes (in mm3,
subsequently converted to ml) for these labels were summed up to derive
estimates of total gray and white matter volume as well as total brain
volume. The FreeSurfer software and its documentation can be down-
loaded from http://surfer.nmr.mgh.harvard.edu.
Discovery sample data
Summary results including risk variants, their P-values and associated odds
ratios from the recent international collaborative GWAS on 9394 SCZ cases
and 12 462 healthy controls were collected from the Psychiatric GWAS
Consortium.1 Relevant information on the methods used by the
consortium is described elsewhere.1
Genetic analysis of the target sample
Genotyping of the Italian target sample was performed using a semi-custom
Axiom myDesign genotyping array (Affymetrix, Santa Clara, CA, USA), based
on a CEU (Caucasian residents of European ancestry from UT, USA) marker
backbone including 518 722 SNPs, and a custom marker set including 102
537 SNPs. The array was designed using the Axiom Design center (www.
affymetrix.com), applying diverse selection criteria.19 Genotyping was
performed by Affymetrix on a GeneTitan platform. Several quality control
steps were applied (SNP call rate >97%, Fisher’s linear discriminant, hetero-
zygous cluster strength offset, homozygote ratio offset). In a subsequent
step, some SNPs were ﬁltered out based on minor allele frequency o0.02 or
if the χ2-test for Hardy–Weinberg equilibrium was o1×10−6.19 For the
present study, SNPs on chromosomes X and Y and mitochondrial DNA were
excluded, leaving 574 505 SNPs for analyses. This SNP set was then used to
calculate multidimensional scaling components in order to control for
population stratiﬁcation. Similarly, the inbreeding coefﬁcient was calculated
by making use of a pruned version of this SNP set. MDS components and
inbreeding coefﬁcients were calculated using PLINK.20
Derivation of polygenic scores
Polygenic SCZ risk scores. Markers directly genotyped in the target sample
were used for the generation of this score. As described in the Psychiatric
Genomics Consortium guidelines regarding polygenic risk proﬁle analyses
(http://pgc.unc.edu), all SNPs in the extended major histocompatibility
complex region were removed at this stage, except one representing the
best hit in this region. PSS were calculated following the methods
described by Purcell et al.2 In brief, sets of SNPs with P-values below
different cutoffs (0.0001; 0.0005; 0.001; 0.005; 0.01; 0.05; 0.1; 0.2; 0.3; 0.4) in
the discovery sample were deﬁned. In order to identify polygenic effects
Table 1. Variance explained (R2) and P-values of the association of PSS (based on different P-value thresholds) and of PWM (based on the complete
or partial SNP set) with total brain, white matter and gray matter volumes in the healthy target sample (N= 122)
No. SNPs Total brain White matter Gray matter
R2 change P-value R2 change P-value R2 change P-value
PSS (polygenic SCZ risk score)
Po0.0001 106 −0.007 0.613 −0.008 0.740 −0.007 0.590
Po0.0005 311 −0.009 0.928 −0.010 0.903 −0.009 0.801
Po0.001 482 0.007 0.180 −0.009 0.776 0.023 0.054
Po0.005 1480 −0.006 0.559 −0.009 0.983 0.000 0.320
Po0.01 2528 −0.005 0.507 −0.006 0.558 −0.005 0.570
Po0.05 8555 −0.006 0.582 −0.007 0.613 −0.008 0.710
Po0.1 14 491 −0.009 0.819 −0.008 0.678 −0.009 0.999
Po0.2 24 870 −0.008 0.689 −0.009 0.856 −0.007 0.624
Po0.3 33 660 −0.007 0.635 −0.010 0.941 −0.005 0.489
Po0.4 41 398 −0.007 0.661 −0.007 0.941 −0.003 0.445
PWM (polygenic white matter score)
Complete SNP set 185 −0.008 0.719 −0.009 0.744 −0.001 0.333
Partial set 142 −0.002 0.391 −0.009 0.872 0.006 0.187
Abbreviations: SCZ, schizophrenia; SNP, single-nucleotide polymorphism. R2 refers to R2 adjusted for the number of predictors in the model.
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due to independent SNPs in linkage equilibrium, each SNP set was pruned
based on a pairwise r2 threshold of 0.25 and a sliding window of 50 SNPs
shifting 5 SNPs at each step (see Table 1 for the total number of SNPs
ﬁnally included under each P-value threshold). For each subject in the
target sample, a PSS was calculated for the different P-value thresholds. For
each SNP, the number of risk variants (0, 1, 2) an individual carries was
multiplied by the logarithm of the odds ratio for that particular variant.
Both pruning and scoring were performed using PLINK.20
Polygenic white matter scores. A total of 66 out of the 186 SNPs that consti-
tute the PWM7 were directly genotyped in the Axiom array. The remaining
120 SNPs were imputed using IMPUTE v2.2.21 Imputation was performed with
the 1000 Genomes Project Phase 1 (March 2012) reference panel, and best-
guess genotypes were used for polygenic scoring. One of the SNPs
(rs9880959) could not be imputed. Mean± s.d. imputation quality score
was 0.906±0.127. First, PWM including the complete set of 185 SNPs was
calculated following the previously described methods. Second, an alterna-
tive PWM was calculated using a partial set of 142 SNPs, including only those
directly genotyped and those with imputation quality score ⩾0.9 (Figure 1).
Statistical analysis
Standardized values of total brain, white matter and gray matter volumes
were obtained after correction for age, gender and intracranial volume.
These corrected brain dimensions were used as dependent variables in a
linear regression model. Ten multidimensional scaling components, the
inbreeding coefﬁcient and the number of SNPs used to calculate the poly-
genic scores were selected as covariates of potential relevance. R2 values
derived from a model including all of these covariates were subtracted
from R2 values from a model including covariates plus the respective
polygenic score. The difference between the R2 adjusted for the number of
predictors in the model represents the increase in the variance explained
attributable to the polygenic score. All these calculations as well as sign
tests were carried out with SPSS 17.0 (IBM-Deutschland GmbH, Munich,
Germany).22 PLINK20 was used for testing association of each of the 185
SNPs belonging to PWM with the different brain volumetric variables.
QUANTO software23 was used for power calculations in the target sample.
RESULTS
The target sample comprised a total of 122 Italian subjects (56
males, 66 females), aged 45.0 ± 17.0 (mean± s.d.) years (range
20–80), with an education level of 14.4 ± 3.7 (mean± s.d.) years
(range 5–24 years). Mean volumes (± s.d.) (ml) were 978.1 ±112.7,
407.1 ± 55.7 and 551.5 ± 65.5 for total brain, white matter and gray
matter, respectively.
PSS were not associated (P>0.05 in all comparisons) with any of
the brain dimensions in the present sample of healthy subjects,
irrespective of the P-value cutoffs selected for analysis (Table 1).
The 'best result' obtained was a trend toward association
(P= 0.054) with gray matter volume at P cutoff o0.001 leading
to a change in adjusted R2 of 0.023. Gray matter, however, was not
associated with PSS in the original study.7
Similarly, PWM analysis did not yield any signiﬁcant association
(P>0.05 in all comparisons) either with white matter volume, the
main variable of interest or the other brain volumes studied. This
lack of signiﬁcance was true for both the complete and the partial
set of SNPs (Table 1; Figure 1). When the individual effects of these
markers on volumetric variables were evaluated, none of the P-
values survived Bonferroni correction (Supplementary Table S1).
Sign tests for consistency between the original study7 and the
present one, based on the sign of the beta coefﬁcients on imaging
variables, did not yield signiﬁcant results (P>0.05).
As the mean age of our target sample was signiﬁcantly
(P= 0.0001) higher than the mean age of the sample analyzed in
the original publication (mean± s.d.: 45.0 ± 17.0 versus 32.3 ± 12.2
years, respectively),7 we performed an exploratory analysis in our
sample, excluding subjects aged >55 years. Also, the resulting
smaller subset (N= 80), with a mean age of 34.5 ± 9.67 years (no
longer different from the original sample; P= 0.166), did not reveal
the slightest trend toward an association (all comparisons P>0.05)
(Supplementary Table S2).
DISCUSSION
A recent original publication7 reported an effect of GWAS-
identiﬁed SCZ risk variants, when compiled to polygenic scores,
on total brain and white matter volumes in SCZ and even more
pronounced in healthy individuals. The present study has not
been able to replicate these effects in an independent sample of
healthy subjects.
Differences between the original publication and the present
study that have to be discussed as potential causal contributors to
the lack of reproducibility are: the sample size (N= 142 versus
N= 122), the ethnic background, the age distribution (mean age
32 versus 45 years), the array technology (Affymetrix versus
Illumina, San Diego, CA, USA), the SNP imputation quality and the
magnetic ﬁeld strength of the MRI scanner underlying volumetry
(1.5 versus 3 T).
The healthy sample analyzed in our study (N= 122) had 80%
power to detect R2 >6.2% between PSS and the different brain
volumes selected for analysis. In the original report, the amount of
maximum variance explained ranged from 4.8 to 5.1%, regarding
total brain and white matter volumes, respectively. Thus, the
power of the present sample was below 80%. Therefore, a reduced
power cannot be entirely excluded as one reason for the non-
replication results presented here. However, the results of the sign
tests regarding the comparability between samples, together with
the complete lack of any 'signal' in the polygenic approach,
suggest that a lack of power may not account for the lack of
replication. Of course, a winner’s curse effect in the original study
cannot be entirely excluded.
Regarding the ethnic background, correction for population
stratiﬁcation by introduction of multidimensional scaling compo-
nents as covariates should have controlled for potential stratiﬁca-
tion within our replicate sample. We included as many as 10
multidimensional scaling components as covariates to diminish
bias from population stratiﬁcation. Reducing them in an
exploratory fashion to four did not signiﬁcantly alter the results,
arguing against overcorrection bias (data not shown). Both
samples are of European Caucasian origin, pointing to a high
degree of similarity in their common genomic variation involved
in disease or phenotype susceptibility.
The signiﬁcant age difference between the original study
sample and our cohort may also have a part in the failure to
reproduce the associations described in the original paper.
However, exploratory reduction of the mean age of our study
Figure 1. Scheme of source and number of single nucleotide
polymorphisms (SNPs) used to calculate polygenic white matter
scores (PWM).
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group by removing individuals that were >55 years old failed to
provide even the least signal of an association between PSS or
PWM and total brain or white matter dimensions.
The original study7 used the Illumina HumanHap550 beadchip
(Illumina) for SNP genotyping, whereas we used semi-custom Axiom
(Affymetrix). As both arrays are based on very similar principles
regarding linkage disequilibrium thresholds for genome-wide cover-
age, have a similar number of markers and are identical regarding
about 30% of the SNPs, this technological difference does not seem
to account for non-reproducibility of the original publication.
SNP imputation quality was nearly perfect in 76 SNPs, whereas 43
SNPs did not reach the highest quality threshold. However, as
described in the Materials and Methods section, the overall mean
quality score was >0.9. Nevertheless, with a total of 142/185 SNPs, at
least an approximation of the PWM results should have been reached.
The scanner in which MRI sequences were acquired is different in
the original study (1.5 T) compared with the present work (3 T). In
fact, 3 T scanners increase baseline magnetization, leading to an
about twofold increase in signal-to-noise ratio, which, in turn,
improves accuracy and reproducibility of tissue classiﬁcation results
and thus sensitivity of volumetry regarding morphometric
differences.24 Therefore, also this difference should not be critical
for our failure to replicate the previous results. Moreover, the deep
methodological (software) differences between the two segmenta-
tion processes used in the original7 versus our study might account
for the mismatch between the two samples. In this regard, it has to
be pointed out that the method used here is nowadays the gold
standard in brain segmentation, whereas the method employed by
Terwisscha van Scheltinga et al.7 is based on older software.
Taken together, even with the limitations of our replication
sample discussed above (and always bearing in mind the possibility
of a winner’s curse effect in the original study), at least a ‘signal in
the right direction’ would have to be expected if the PSS or PWM
associations with brain dimensions were of general validity. In light
of the obvious interest of studying effects of polygenic risk scores
on speciﬁc subphenotypes of relevance for complex psychiatric
disorders, our results admonish that replication studies are
absolutely essential for this kind of analyses. This all the more as
polygenic settings of interest cannot easily be explored in animal
models to conﬁrm their speciﬁc importance. It remains to be
established whether by including even larger numbers of indivi-
duals in case–control GWAS, the heterogeneity problem of SCZ or
other mental diseases (and of health) will be solved. Although much
more labor intense than GWAS, large-scale phenotype-based
genetic association studies will be pivotal for further investigating
the genotype contribution to complex disease phenotypes, thereby
extending and complementing the GWAS efforts.
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